Expression of multidrug resistance-related proteins p- glycoproteinglutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma

Cancer Investigation

Volumn 26, Issue 4, 2008, Pages 344-351

  Shi, Hongcan ^a   Lu, Dan ^a   Shu, Yusheng ^a   Shi, Weiping ^a   Lu, Shichun ^a   Wang, Kang ^a  

^a YANGZHOU UNIVERSITY   (China)

Author keywords

Chemoresistance; Gastric Cardiac Neoplasms; Glutathione s transferases; Lung resistance protein; Multidrug resistance; P glycoprotein; Topoisomerase

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; CARDIA CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; STOMACH ADENOCARCINOMA; TISSUE SECTION;

ADENOCARCINOMA; ADULT; AGED; CARDIA; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE S-TRANSFERASE PI; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; ORGANELLES; P-GLYCOPROTEIN; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 42649122978     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701788072     Document Type: Article

References (36)

1. Ito, H.; Clancy, T.E.; Osteen, R.T.; Swanson, R.S.; Bueno, R.; Sugarbaker, D. J.; Ashley, S.W.; Zinner, M.J.; Whang, E.E. Adenocarcinoma of the Gastric Cardia: What Is the Optimal Surgical Approach? J Am Coll Surg 2004, 199, 880-886.
2. Siewert, J.R.; Feith, M.; Werner, M.; Stein, H.J.; Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 2000, 232, 353-361.
3. de Manzoni, G.; Pedrazzani, C.; Pasini, F.; Di Leo, A.; Durante, E.; Castaldini, G.; Cordiano, C. Results of surgical treatment of adenocarcinoma of the gastric cardia. Ann Thorac Surg 2002, 73, 1035-1040.
4. Balon, J.M.; Triboulet, J.P.Surgical management of and long-term survival after adenocarcinoma of the cardia. Br J Surg 2002, 89, 1156-1163.
5. Peer, D.; Margalit, R. Fluoxetine and reversal of multidrug resistance. Cancer Letters 2006, 237, 180-187.
6. Triller, N.; Korosec, P.; Kern, I.; Kosnik, M.; Debeljak, A. Multidrug resistance in small cell lung cancer: Expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease. Lung Cancer 2006, 54, 235-240.
7. Lavie, Y.; Liscovitch, M.Changes in lipid and protein constituents of rafts and caveolae in multidrug resistant cancer cells and their functional consequences. Glycoconj J 2000, 17, 253-259.
8. Lavie, Y.; Fiucci, G.; Liscovitch, M. Upregulation of caveolin in multidrug resistant cancer cells: functional implications. Adv Drug Delivery Rev 2001, 49, 317-323.
9. Litman, T.; Druley, T.E.; Stein, W.D.; Bates, S.E. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001, 58, 931-959.
10. Leonard, G.D.; Fojo, T.; Bates, S.E. The role of ABCtransporters in clinical practice. Oncologist 2003, 8, 411-424.
11. Ambudkar, S.V.; Kimchi-Sarfaty, C.; Sauna, Z.E.; Gottesman, M.M. P-glycoprotein: from genomics to mechanism. Oncogene 2003, 22, 7468-7485.
12. Fojo, T.; Bates, S. Strategies for reversing drug resistance. Oncogene 2003, 22, 7512-7523.
13. Filipits, M. Mechanisms of cancer: multidrug resistance. Drug Discovery Today: Disease Mechanisms 2004, 1, 229-234.
14. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000, 92, 1295-1302.
15. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: role of ATPdependent transporters. Nat Rev Cancer 2002, 2, 48-58.
16. Kickhoefer, V.A.; Rajavel, K.S.; Scheffer, G.L.; Dalton, W.S.; Scheper, R.J.; Rome, L.H. Vaults are up-regulated in multidrug resistant cancer cell lines. J Biol Chem 1998, 273, 8971-8974.
17. Cerfa, E.; Gaspera, R.; Rychnovskyb, S.; Changc, X.; Buysea, F.; Ruysschaert, J.M. Multidrug resistance protein 1 is not associated to detergent-resistant membranes. Biochem Biophys Res Commun 2007, 355, 1025-1030.
18. Callaghana, R.; Fordb, R.C.; Kerrc, I.D. The translocation mechanism of P-glycoprotein. FEBS Letters 2006, 580, 1056-1063.
19. Sisodiya, S.M.; Martinian, L.; Scheffer, G.L.; van der Valk, P.; Scheper, R.J.; Harding, B.N.; Thom, M. Vascular colocalization of P-glycoprotein, multidrug-resistance associated protein 1, breast cancer resistance protein and major vault protein in human epileptogenic pathologies. Neuropathol Appl Neurobiol 2006, 32, 51-63.
20. Tanaka, P.Y.; Calore, E.E. P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients. Pathol Res Pract 2007, 203, 1-7.
21. Leith, C.P.; Kopecky, K.J.; Chen, I.M.; Eijdems, L.; Slovak, M.L.; McConnell, T.S.; et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acutemyeloid leukaemia: a Southwest Oncology Group study. Blood 1999, 94, 1086-1099.
22. Soh, Y.; Gotoy, S.; Kitajima, M.; Moriyama, S.; Kotera, K.; Nakayamaz, T.; Nakajimax, H.; Kondoy, T.; Ishimaru, T.; Nuclear Localisation of Glutathione S-transferase π is an Evaluation Factor for Drug Resistance in Gynaecological Cancers. Clin Oncol 2005, 17, 264-270.
23. Gate, L.; Majumdar, R.S.; Lunk, A.; Tew, K.D. Influence of Glutathione S-Transferase pi and p53 Expression on Tumor Frequency and Spectrum in Mice. Int J Cancer 2005, 113, 29-35.
24. Gate, L.; Tew, K.D. Glutathione S-transferases as emerging therapeutic targets. Expert Opin Ther Targets 2001, 5, 477-489.
25. Goto, S.; Kamada, K.; Soh, Y.; Ihara, Y.; Kondo, T.; et al. Significance of nuclear glutathione S-transferase pi in resistance to anticancer drugs. Jpn J Cancer Res 2002, 93, 1047-1056.
26. Goto, S.; Ihara, Y.; Urata, Y.; Izumi, S.; Abe, K.; Koji, T.; Kondo, T. Doxorubicin-induced DNA intercalation and scavenging by nuclear glutathione S-transferase pi. FASEB J 2001, 15, 2702-2714
27. Dingemans, A.M.C.; van Ark-Otte, J.; Span, S.; Scagliotti, G.V.; van der Valk, P.; Postmus, P.E.; Giaccone, G. Topoisomerase II_ and other drug resistance markers in advanced non-small cell lung cancer. Lung Cancer 2001, 32, 117-128.
28. Nielsen, D.; Maare, C.; Skovsgaard, T. Cellular resistance to anthracyclines. Gen Pharmacol 1996, 27, 251-255.
29. Giaccone, G. DNA topoisomerases and topoisomerase inhibitors. Pathol Biol. 1994, 42, 346-352.
30. Gotlieb, W.H.; Goldberg, I.; Weisz, B.; Davidson, B.; Novikov, I.; Kopolovic, J.; Ben-Baruch, G. Topoisomerase II Immunostaining as a Prognostic Marker for Survival in Ovarian Cancer. Gynecologic Oncology 2001, 82, 99-104.
31. Scheper, R.J.; Broxterman, H.J.; Scheffer, G.L.; Kaaijk, P.; Dalton, W.S.; van Heijningen, T.H.; van Kalken, C.K.; Slovak, M.L.; de Vries, E.G.; van der Valk, P. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein mediated multidrug resistance. Cancer Res 1993, 53, 1475-1479.
32. Izquierdo, M.A.; Shoemaker, R.H.; Flens, M.J.; Scheffer, G.L.; Wu, L.; Prather, T.R.; Scheper, R.J. Overlapping phenotypes of multidrug resistance amongpanels of human cancer-cell lines. Int J Cancer 1996, 65, 230-237.
33. Berger, W.; Elbling, L.; Micksche, M. Expression of the major vault protein LRP in human non-small cell lung cancer cells: activation by short-term exposure to antineoplastic drugs. Int J Cancer 2000, 88, 293-300.
34. Laureysa, G.; Benoita, Y.; Philippéb, Jan. Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia. European Journal of Cancer 2006, 423, 295-309.
35. Izquierdo, M.A.; Van der Zee, A.G.J.; Vermorken, J.B.; Van der Valk, P.; Belien, J.A.M.; Giaccone, G.; Scheffer, G.L.; Flens, M.J.; Pinedo, H.M.; Kenemans, P.; Meijer, C.J.L.M.; De Vries, E.G.E.; Scheper, R.J.Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995, 87, 1230-1232.
36. Lagarde, S.M.; ten Kate, F.J.W.; Richel, D.J.; Offerhaus, G.J.A.; van Lanschot, J.J.B. Molecular Prognostic Factors in Adenocarcinoma of the Esophagus and Gastroesophageal Junction. Ann Surg Oncol 2006, 14, 977-991.